To evaluate the frequency of neurological-immune-related adverse events (n-irAES) and the associated demographic/clinical characteristics of oncological patients treated with immune-checkpoint inhibitors (ICIs) at the University of Cincinnati (UC).
No takes yet. Share an insight, caveat, or question.
Marsili et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: